FTC Accuses Telehealth Leader Hims & Hers of Selling Patient Health Secrets to Meta and Snap

The Federal Trade Commission has taken direct aim at one of telehealth’s biggest names. On July 29, 2026, the agency, joined by California and Utah, filed suit against Hims & Hers Health in federal court in San Francisco. The complaint paints a troubling picture. A company that built its brand on convenient, private access to treatments for erectile dysfunction, hair loss, mental health and weight management stands accused of funneling sensitive patient details straight to advertisers.

Short. Simple. And serious.

According to the FTC press release, Hims & Hers placed tracking tools from Meta, Snap and other platforms across its website and app. These pixels and events captured what users searched for, what conditions they disclosed on intake forms, even whether they clicked on pages about sexual wellness or hair regrowth. That information then flowed to advertisers. All while the company told customers their data would stay private.

But the allegations run deeper. The FTC says Hims & Hers enrolled users in automatic subscription plans moments after they completed online questionnaires. Many never spoke with a doctor. Charges hit their cards before any consultation occurred. Canceling proved difficult. Buttons were hidden. Processes unclear. Early refills billed without clear warning. The agency cites consumer complaints describing exactly this experience.

Health Data for Sale

Christopher Mufarrige, director of the FTC’s Bureau of Consumer Protection, called the conduct a “troubling scenario.” He said the company “shared consumers’ sensitive health information with third parties for advertising purposes, even though it promised to keep that information private.” The suit alleges violations of the FTC Act, the Restore Online Shoppers’ Confidence Act, California’s False Advertising Law and Unfair Competition Law, plus Utah’s Consumer Sales Practices Act.

Examples cited in the complaint include users who revealed struggles with erectile dysfunction or hair loss. Their data, the FTC claims, helped Meta and Snap deliver targeted ads. The trackers didn’t stop at basic demographics. They recorded health-specific actions. And they did so despite Hims & Hers’ own privacy policy promising control and confidentiality.

This isn’t the first time the FTC has moved against digital health firms. The agency previously settled cases with Cerebral, Monument, GoodRx and BetterHelp over similar data-sharing practices. Each time the pattern looked familiar. Promises of privacy. Tracking pixels. Revenue from advertising partnerships. Yet the Hims & Hers case stands out for its scale. The company serves millions. It went public. Its stock trades under ticker HIMS. And it has spent heavily on marketing that emphasizes discretion.

Stock reaction proved telling. Shares dropped sharply on news of the filing, though they recovered some ground the next day amid a broader market rally. Analysts from Citi, Bank of America, Morgan Stanley and others issued notes maintaining neutral or equal-weight ratings. Price targets ranged from $21 to $35. Many viewed the suit as an escalation of an investigation that began nearly three years earlier. Hims & Hers had already disclosed the probe in securities filings and set aside a $15 million reserve.

But the company pushed back hard. In a statement posted to its investor site, Hims & Hers called the claims “baseless.” The full response reads: “This lawsuit disregards substantial evidence we provided the FTC during its nearly three-year investigation, ignores established state laws and industry standards in telehealth, and contorts the law to try to manufacture claims. This is not enforcement grounded in consumer protection; it is an effort to generate headlines at our expense. We are confident in our position and will vigorously defend ourselves against these baseless claims.”

The company added that its privacy policy “makes clear that they may choose how their data is used” and that information patients share with healthcare providers “is used only to deliver care.” Executives noted alignment with the FTC’s new Healthcare Task Force on goals of affordable, high-quality care. Millions have relied on the platform since 2017, they said. Trust remains the foundation.

Industry observers on X reacted quickly. Some called the suit a “nothing burger” that markets had already priced in. Others worried it could chill telehealth innovation or scare off institutional investors. One investor account posted: “The FTC lawsuit is an escalation not a new surprise. The real questions now are: Is the final penalty materially above what Hims already reserved? Will this force changes to advertising or subscription practices?”

Recent coverage adds context. A July 30 story from The Record highlighted the privacy implications for the broader sector. Breitbart noted the suit accuses the firm of sharing data “even though it promised users that its services were private and secure.” And a CoinTicker piece tied the allegations to both data practices and the subscription traps.

The case now sits in the Northern District of California. The FTC seeks a permanent injunction, civil penalties, consumer redress and other relief. No settlement talks appear active after the investigation phase ended without resolution.

So what happens next? Regulators want stronger guardrails around health data in advertising ecosystems. Telehealth companies face pressure to separate clinical information from marketing engines. Advertisers like Meta and Snap may need to revisit how they accept signals from health platforms. And patients? They’re left wondering whether that online questionnaire really stayed confidential.

Hims & Hers built a business on convenience and discretion. The FTC now argues the company sacrificed the latter for growth. The coming months of litigation will test which story holds. One thing is clear. The era of unchecked pixel tracking in sensitive health categories is under fresh scrutiny. Courts will decide how expensive that scrutiny becomes.